Balchem Crecimiento futuro

Future controles de criterios 1/6

Balchem se prevé un crecimiento anual de los beneficios y los ingresos de 10.4% y 5.2% respectivamente. Se prevé que el BPA sea de grow en 9.8% al año. Se prevé que la rentabilidad de los fondos propios sea de 10.7% en 3 años.

Información clave

14.5%

Tasa de crecimiento de los beneficios

13.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Chemicals	15.2%
Tasa de crecimiento de los ingresos	4.9%
Rentabilidad financiera futura	12.1%
Cobertura de analistas	Low
Última actualización	26 Feb 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Balchem Corporation's (NASDAQ:BCPC) Popularity With Investors Is Clear

Mar 21

Is Balchem Corporation (NASDAQ:BCPC) Expensive For A Reason? A Look At Its Intrinsic Value

Mar 05

Balchem: Potential Turnaround Is In The Price

Feb 21

These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Reasonably Well

Feb 18

Balchem Corporation (NASDAQ:BCPC) Shares Could Be 26% Above Their Intrinsic Value Estimate

Nov 29

Here's What To Make Of Balchem's (NASDAQ:BCPC) Decelerating Rates Of Return

Sep 20

Balchem: Acquisitions And Cost Pressures Draw Attention

Sep 12

Balchem (NASDAQ:BCPC) Seems To Use Debt Rather Sparingly

Sep 05

Balchem to acquire Cardinal Associates or Bergstrom Nutrition

Aug 30

Is Balchem Corporation (NASDAQ:BCPC) Worth US$138 Based On Its Intrinsic Value?

Aug 22

Should You Be Adding Balchem (NASDAQ:BCPC) To Your Watchlist Today?

Aug 08

Balchem Q2 2022 Earnings Preview

Jul 28

Balchem: On The M&A Road Again

Jun 28

Balchem: A New Growth Stage Is Just Beginning

Jun 02

Slowing Rates Of Return At Balchem (NASDAQ:BCPC) Leave Little Room For Excitement

May 30

Balchem Corporation's (NASDAQ:BCPC) Intrinsic Value Is Potentially 17% Below Its Share Price

May 18

Does Balchem (NASDAQ:BCPC) Deserve A Spot On Your Watchlist?

May 02

Does Balchem (NASDAQ:BCPC) Have A Healthy Balance Sheet?

Mar 28

Balchem (NASDAQ:BCPC) Hasn't Managed To Accelerate Its Returns

Feb 26

Balchem (NASDAQ:BCPC) Could Easily Take On More Debt

Dec 23

Return Trends At Balchem (NASDAQ:BCPC) Aren't Appealing

Nov 18

We Think Balchem (NASDAQ:BCPC) Can Manage Its Debt With Ease

Sep 22

Here's What To Make Of Balchem's (NASDAQ:BCPC) Decelerating Rates Of Return

Aug 16

Balchem: Good Quarterly Performance Priced In

Aug 02

These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Safely

Jun 12

Returns On Capital At Balchem (NASDAQ:BCPC) Have Stalled

May 13

Balchem EPS beats by $0.03, beats on revenue

Apr 30

Balchem: All Eyes On M&A And Autism Drug

Apr 26

Is Balchem (NASDAQ:BCPC) A Risky Investment?

Mar 14

How Many Balchem Corporation (NASDAQ:BCPC) Shares Have Insiders Sold, In The Last Year?

Feb 27

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:BCPC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	1,018	145	173	207	2
12/31/2024	965	128	161	201	2
12/31/2023	922	109	146	184	N/A
9/30/2023	926	103	117	158	N/A
6/30/2023	941	99	106	153	N/A
3/31/2023	946	99	117	166	N/A
12/31/2022	942	105	89	139	N/A
9/30/2022	923	109	91	141	N/A
6/30/2022	877	109	95	139	N/A
3/31/2022	842	102	86	127	N/A
12/31/2021	799	96	123	161	N/A
9/30/2021	767	93	128	164	N/A
6/30/2021	744	90	125	160	N/A
3/31/2021	715	88	134	169	N/A
12/31/2020	704	85	117	150	N/A
9/30/2020	689	83	108	136	N/A
6/30/2020	673	82	116	143	N/A
3/31/2020	661	81	99	125	N/A
12/31/2019	644	80	96	124	N/A
9/30/2019	641	80	103	131	N/A
6/30/2019	637	78	94	121	N/A
3/31/2019	639	78	91	116	N/A
12/31/2018	644	79	99	119	N/A
9/30/2018	639	100	87	110	N/A
6/30/2018	635	97	87	112	N/A
3/31/2018	618	94	84	113	N/A
12/31/2017	595	90	83	111	N/A
9/30/2017	576	64	N/A	107	N/A
6/30/2017	564	62	N/A	97	N/A
3/31/2017	556	60	N/A	101	N/A
12/31/2016	553	56	N/A	108	N/A
9/30/2016	545	56	N/A	105	N/A
6/30/2016	547	56	N/A	110	N/A
3/31/2016	543	56	N/A	107	N/A
12/31/2015	552	60	N/A	104	N/A
9/30/2015	582	63	N/A	115	N/A
6/30/2015	603	64	N/A	108	N/A
3/31/2015	600	59	N/A	102	N/A
12/31/2014	541	53	N/A	85	N/A
9/30/2014	460	45	N/A	65	N/A
6/30/2014	387	41	N/A	60	N/A
3/31/2014	339	43	N/A	62	N/A
12/31/2013	337	45	N/A	56	N/A
9/30/2013	336	44	N/A	49	N/A
6/30/2013	323	43	N/A	46	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: BCPC(10.4% al año) es superior a la tasa de ahorro (2.2%).

Beneficios vs. Mercado: Se prevé que los beneficios (14.5% al año) de BCPC crezcan menos que el mercado US (14.6% al año).

Beneficios de alto crecimiento: BCPCSe prevé que los beneficios de la empresa crezcan, pero no significativamente.

Ingresos vs. Mercado: BCPC(5.2% al año) se prevé que crezca más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: BCPCSe prevé que los ingresos de la empresa (5.2% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: BCPCSe prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (10.7%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Balchem Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 8.4% to US$145

Price target increased to US$170

Price target increased to US$154

Price target increased to US$152

Price target increased to US$144

Price target increased to US$133

Recent updates

Balchem Corporation's (NASDAQ:BCPC) Popularity With Investors Is Clear

Is Balchem Corporation (NASDAQ:BCPC) Expensive For A Reason? A Look At Its Intrinsic Value

Chairman recently sold US$4.6m worth of stock

Chairman notifies of intention to sell stock

Balchem: Potential Turnaround Is In The Price

These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

Now 21% overvalued after recent price rise

Balchem Corporation to Report Q4, 2023 Results on Feb 16, 2024

Returns On Capital At Balchem (NASDAQ:BCPC) Have Stalled

Upcoming dividend of US$0.79 per share at 0.5% yield

Balchem Corporation's (NASDAQ:BCPC) P/E Is On The Mark

Balchem Corporation Announces Dividend, Payable on January 19, 2024

Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)

Price target decreased by 8.4% to US$145

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Balchem (NASDAQ:BCPC) Has A Pretty Healthy Balance Sheet

Balchem Corporation to Report Q3, 2023 Results on Oct 27, 2023

Independent Director recently sold US$500k worth of stock

The Returns At Balchem (NASDAQ:BCPC) Aren't Growing

Balchem Corporation Announces Board Appointments, Effective as of September 6, 2023

A Look At The Intrinsic Value Of Balchem Corporation (NASDAQ:BCPC)

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Balchem (NASDAQ:BCPC) A Risky Investment?

Balchem Corporation to Report Q2, 2023 Results on Jul 28, 2023

Some Investors May Be Worried About Balchem's (NASDAQ:BCPC) Returns On Capital

Calculating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)

Senior VP & CTO recently sold US$300k worth of stock

First quarter 2023 earnings: EPS exceeds analyst expectations

Do Balchem's (NASDAQ:BCPC) Earnings Warrant Your Attention?

Independent Director recently sold US$381k worth of stock

We Think Balchem (NASDAQ:BCPC) Can Stay On Top Of Its Debt

Full year 2022 earnings: EPS misses analyst expectations

Balchem Corporation to Report Q4, 2022 Results on Feb 24, 2023

Balchem (NASDAQ:BCPC) Hasn't Managed To Accelerate Its Returns

Here's Why We Think Balchem (NASDAQ:BCPC) Is Well Worth Watching

Upcoming dividend of US$0.71 per share

Is Balchem (NASDAQ:BCPC) A Risky Investment?

Balchem Corporation Announces Dividend, Payable on January 20, 2023

Balchem Corporation (NASDAQ:BCPC) Shares Could Be 26% Above Their Intrinsic Value Estimate

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Balchem Corporation to Report Q3, 2022 Results on Nov 04, 2022

Insufficient new directors

James C. Hyde, Senior Vice President and General Manager, Human Nutrition & Health, Notifies Balchem Corporation His Intent to Retire from His Role

Here's What To Make Of Balchem's (NASDAQ:BCPC) Decelerating Rates Of Return

Balchem: Acquisitions And Cost Pressures Draw Attention

Balchem (NASDAQ:BCPC) Seems To Use Debt Rather Sparingly

Balchem to acquire Cardinal Associates or Bergstrom Nutrition

Is Balchem Corporation (NASDAQ:BCPC) Worth US$138 Based On Its Intrinsic Value?

Should You Be Adding Balchem (NASDAQ:BCPC) To Your Watchlist Today?

Insider recently sold US$175k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Balchem Q2 2022 Earnings Preview

Balchem Corporation to Report Q2, 2022 Results on Jul 29, 2022

Balchem: On The M&A Road Again

Balchem Corporation (NasdaqGS:BCPC) completed the acquisition of Kappa Bioscience AS from Verdane Edda managed by Verdane and others on June 21, 2022.

Balchem Corporation (NasdaqGS:BCPC) entered into an agreement to acquire Kappa Bioscience AS from Verdane Edda managed by Verdane and others.

Balchem Corporation Announces Resignation of Mark Stach as Company Secretary

Balchem: A New Growth Stage Is Just Beginning

Slowing Rates Of Return At Balchem (NASDAQ:BCPC) Leave Little Room For Excitement

Balchem Corporation's (NASDAQ:BCPC) Intrinsic Value Is Potentially 17% Below Its Share Price

Does Balchem (NASDAQ:BCPC) Deserve A Spot On Your Watchlist?

Balchem Corporation, Annual General Meeting, Jun 23, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Balchem Corporation to Report Q1, 2022 Results on Apr 29, 2022

Does Balchem (NASDAQ:BCPC) Have A Healthy Balance Sheet?

Balchem (NASDAQ:BCPC) Hasn't Managed To Accelerate Its Returns